Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares?
Tempus AI's founder-CEO reduced an indirect stake by about 4% through a pre-scheduled trading plan, retaining roughly 6.5 million shares as the company pursues a major acquisition.
Overview
Eric P. Lefkofsky, CEO and Chairman of Tempus AI (NASDAQ:TEM), reported a sale of 250,000 shares of Class A Common Stock on July 28, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($42.06); post-transaction value based on July 28, 2026 market close ($42.90).
Details
Tempus AI is a healthcare technology company with a market capitalization of $7.8 billion and approximately 3,800 employees based in Chicago. The company operates a full-stack platform that combines clinical software, laboratory diagnostics, and artificial intelligence-driven analytics to deliver precision medicine solutions. Despite achieving $1.4 billion in TTM revenue, the company is currently unprofitable with a net loss of $254.4 million, reflecting significant investments in platform development and market expansion within the high-growth precision diagnostics sector.
Source
Originally published at www.fool.com.